StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
AXSMBullishEarningsnews
High materiality9/10

Axsome reports strong 3Q revenue growth; SUMMIT trial advances, near-term catalyst

Nov 2, 2026, 7:24 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong quarterly numbers and a meaningful pipeline catalyst (SUMMIT Phase 3 initiated) support near-term upside. Surpassing a $1B annualized run rate is a milestone likely to be interpreted positively, though actual guidance and forward-looking visibility will drive follow-through. Similar earnings-driven moves occurred when AXSM hit notable revenue milestones and announced pipeline progress in prior quarters.

AI summary

What happened, with direct paths to the underlying reporting

Axsome reported 3Q26 net product revenue of $259.7M, up 52% YoY, driven by AUVELITY at $207.6M (+53%), SUNOSI at $48.2M (+47%), and SYMBRAVO at $3.9M (+88%). The company also initiated the SUMMIT Phase 3 trial for AXS-05 in smoking cessation and will host a conference call today at 8:00 AM ET, underscoring robust growth and pipeline momentum.

  • 3Q26 net product revenue: $259.7M, +52% YoY.
  • AUVELITY: $207.6M (+53%), SUNOSI: $48.2M (+47%), SYMBRAVO: $3.9M (+88%).
  • SUMMIT Phase 3 trial initiated for AXS-05; near-term pipeline catalyst.
  • Conference call scheduled for today at 8:00 AM ET.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event